























hreports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 )  77–91
Available  online  at  www.sciencedirect.com
jou rn al hom ep age: ht tp : / /www.e lsev ier .com/ locate / rpor
eview
he current  management  of  mycosis  fungoides
nd Sézary  syndrome  and  the  role  of radiotherapy:
rinciples and  indications
rcole Mazzeoa, Laura Rubinoa, Michela Buglionec, Paolo Antognonib,
tefano Maria Magrini c, Francesco Bertoni c, Manuela Parmiggiania,
aola  Barbieria, Filippo Bertonia,∗
Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy
Department of Radiotherapy, Azienda Ospedaliera Universitaria Ospedale di Circolo e Fondazione Macchi, Varese,
taly
Department of Radiation Oncology, Brescia University, Istituto del Radio “O. Alberti”, Brescia, Italy
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 16 April 2013
eceived in revised form
7 June 2013





otal skin electron irradiation
a  b  s  t  r  a  c  t
Aim: To evaluate the current treatment of mycosis fungoides (MF) and Sézary syndrome (SS)
focusing on the role of radiotherapy (RT), its principles and indications, and the perspectives
of  the novel irradiation technologies.
Background: MF and SS are rare lymphoproliferative diseases whose incidence is increasing.
For  a long time RT has been used as a single modality or in integrated treatment programs
for  these diseases.
Materials and methods: The latest systematic reviews, primary studies and new diagnostic
and treatment guidelines on MF and SS were analyzed. Clinical outcomes together with the
technical aspects and the role of RT were also evaluated.
Results: New data are available on pathogenesis, diagnostic criteria, classiﬁcation and staging
procedures for MF and SS and several local and systemic therapies are proposed. Local-
ized RT can cure “minimal stage” MF while total skin electron beam irradiation (TSEI) may
cure  initial-stage disease and may offer important symptom relief (itch, erythroderma) in a
more  advanced setting. Despite its efﬁcacy, RT is not largely used, mainly because of some
technical difﬁculties but new RT technologies may be proposed to treat large skin surfaces.
Conclusions: New treatment programs offer good results, with median survival of more  than
12  years in early-stage MF, but the median survival of 2.5 years or less in advanced stages isstill a challenge. RT remains an option for all stages with a good cost/effectiveness ratio in a
curative or palliative setting. New RT technologies can overcome some technical problemsof  treating large skin surfaces.
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1.  Background
Cutaneous T-cell lymphomas (CTCLs) are a group of rare
non-Hodgkin’s lymphomas (NHLs) that primarily develop
in the skin (primary cutaneous lymphomas) with clonal
accumulation of neoplastic T lymphocytes, and at times
progress to involve lymph nodes, blood and visceral organs.1
The classiﬁcation of primary cutaneous lymphoma (PCL)
has evolved over the past 50 years. In 2005, WHO  and
EORTC classiﬁcations were combined to obtain the cur-
rent PCL classiﬁcation.2,3 The WHO-EORTC classiﬁcation for
cutaneous lymphomas distinguishes between cutaneous T-
cell lymphomas (CTCL), cutaneous B-cell lymphomas (CBCL),
lymphomas from Natural Killer cells (NK) and a group of
temporarily unclassiﬁable lymphomas with undeﬁned phe-
notypic characteristics.4,5 CTCLs account for 71% of cases of
primary cutaneous lymphomas compared with 29% for cuta-
neous B-cell lymphomas.6 The annual incidence of CTCLs in
USA is 0.3–1 per 100,000 people. Incidence continuously rises
for unknown causes,6,7 and it is correlated with high physician
density, high family income and higher social setting.7 myco-
sis fungoides (MF) is the most common type of CTCLs, and
accounts for about 50–70% of CTCL cases, while Sézary Syn-
drome (SS), a leukemic variant of CTCLs, accounts for 1–3% of
cases.4,6,8
The present paper aims at reviewing the role of radiothe-
rapy within the framework of the current management of
MF and SS and is based on the analysis of data regarding
diagnostic and treatment programs derived from the latest
systematic reviews, primary studies and new guideline pub-
lications; radiotherapy role is discussed in terms of expected
outcomes, toxicity and technical issues.
2.  Diagnosis
MF  is an extranodal NHL of mature T-cells with primary cuta-
neous involvement, deﬁned as a chronic, indolent disease
with slow progression. It is characterized by the develop-
ment of patches, plaques or tumors in the skin. SS is an
erythrodermic, leukemic variant of CTCL, and it is char-
acterized by circulating, atypical, malignant T lymphocytes
with cerebriform nuclei (Sézary cells), erythroderma and
lymphadenopathy. Patients with CTCL may also develop vis-
ceral organ involvement. One unique feature of CTCL is that
the malignant T cell clone expands at the expense of nor-
mal  T cells, creating an immunodeﬁciency, so patients with
CTCL have an increased risk of second malignancies, and
can die due to bacterial infections and septicemia or viral
infections.9–12
Malignant T lymphocytes in MF  and SS are characterized
by the following immunophenotype: CD2+, CD3+, CD4+, CD5+,
CCR4+, CD45RO+, rarely CD8+, and they lack certain T-cell
markers, CD7 and CD26. T cells also express cutaneous lym-
phocyte antigen (CLA) and TH2 cytokines.13
In a subgroup of patients with MF  it has been a large cell
transformation (LCT) documented that is diagnosed when
large cells are present in more  than 25% of lymphoid/tumor
cell inﬁltrates in a skin lesion biopsy.14,15 Diagnosis is based ondiotherapy 1 9 ( 2 0 1 4 ) 77–91
the integration of clinical, histopathologic, immunopathologic
and molecular biological characteristics.16 Complete phys-
ical examination (examination of entire skin, palpation of
peripheral lymph nodes, palpation for organomegaly), biopsy
of suspicious skin sites and immunohistochemical studies of
skin biopsy are essential to conﬁrm the diagnosis. Biopsy of
suspicious lymph nodes and assessment of peripheral blood
for Sézary cells are recommended in the absence of a deﬁni-
tive skin diagnosis. Lymph node biopsy is also recommended
for clinically abnormal nodes (≥1.5 cm in diameter).17 Vis-
ceral disease with the involvement of an organ (e.g., spleen,
liver) other than the skin, nodes or blood should be docu-
mented using imaging studies. PET-CT scan of the body is
recommended in patients with unfavorable features (T2 or
higher, folliculotropic MF or large cell transformation, pal-
pable adenopathy or abnormal blood test results).18 Bone
marrow biopsy may be helpful only in the case of suspected
marrow involvement or evident unexplained blood count
abnormalities.17
3.  Staging  and  prognosis
MF/SS are classiﬁed into 4 clinical stages based on
the TNMB (tumor–node–metastasis–blood), the classiﬁcation
which takes into account the extent of skin involvement based
on the percentage of body surface area (BSA), the presence of
lymph node or visceral disease and the detection of Sézary
cells in the peripheral blood (Table 1).17,19 MF/SS are generally
considered incurable conditions, but it is important to recog-
nize that the majority of patients have an indolent form of the
disease with 65–85% of patients with MF  having stage IA or
IB disease20,21 and living for many  years. The most signiﬁcant
prognostic factors for survival in patients with MF  include age
at presentation, extent and type of skin involvement (T clas-
siﬁcation), overall stage, presence of extracutaneous disease
and peripheral blood involvement.22,23 Long-term follow-up
data from a retrospective study on 525 patients with MF and
SS showed an independent prognostic value of these factors
in a multivariate analysis.23 The risk of disease progression,
development of extracutaneous disease and death due to
MF was correlated with initial T classiﬁcation. The extent of
blood involvement was signiﬁcantly correlated with survival
outcomes. In a study based on data from a large number
of patients with MF/SS (N = 1502) registered in a large cuta-
neous lymphoma database, multivariate analysis showed that
advanced skin (T) stage, peripheral blood involvement, ele-
vated LDH, and folliculotropic MF were independent factors
predictive of an increased risk of disease progression and
death.22 The majority of patients with early-stage disease
(stages IA, IB, and IIA) do not progress to more  advanced-stage
disease, and patients presenting with isolated patch or plaque
disease (T1–T2) may have a median survival of more  than 12
years.23,24
Moreover, patients with stage IA disease do not appear to
have a decreased survival compared with an age-, sex-, and
race-matched population.25 Patients with advanced-stage dis-
ease (stages IIB, III, and IVA) with tumors, erythroderma, and
lymph node or blood involvement, but no visceral involve-
ment, have a median survival of 5 years from time of
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Table 1 – Tumor–node–metastasis–blood (TNMB) classiﬁcation in mycosis fungoides and Sézary syndrome (ISCL/EORTC
revision).17,19
T (skin)
T1 Limited patches, papules, and/or plaques covering <10% of the skin surface. May further stratify into T1a (patch only) vs. T1b
(plaque ± patch)
T2 Patches, papules or plaques covering ≥10% of the skin surface. May further stratify into T2a (patch only) vs. T2b (plaque ± patch)
T3 One or more tumors (diameter ≥1 cm)
T4 Conﬂuence of erythroderma covering >80% of BSA
N (nodes)
N0 No clinically abnormal peripheral lymph nodes, no biopsy required
N1 Clinically abnormal peripheral lymph nodes, histopathology: Dutch grade 1 or NCI LN0–2
1a Clone negative
1b Clone positive
N2 Clinically abnormal peripheral lymph nodes, histopathology: Dutch grade 2 or NCI LN3
2a Clone negative
2b Clone positive
N3 Clinically abnormal peripheral lymph nodes, histopathology: Dutch grade 3–4 or NCI LN4, clone negative or positive
Nx Clinically abnormal peripheral lymph nodes, not conﬁrmed by histopathology
M (viscera)
M0 No visceral organ involvement
M1 Visceral organ involvement (organ speciﬁed and conﬁrmed by histopathology)
B (blood)
B0 Absence of signiﬁcant blood involvement: ≤5% of peripheral blood lymphocytes are atypical (Sézary) cell
B0a Clone negative
B0b Clone positive
B1 Low blood tumor burden: >5% of peripheral blood lymphocytes are atypical (Sézary) cells but does not meet the criteria of B2
B1a Clone negative
B1b Clone positive
B2 High blood tumor burden: ≥1000/mcL Sézary cells with positive clone; one of the following can be substituted for Sézary cells:
CD4/CD8 ≥ 10, CD4 + CD7-cells ≥ 40% or CD4 + CD26-cells ≥ 30%
Classiﬁcation of stages in mycosis fungoides and Sézary syndrome
Stage Tumor Node Metastasis Blood
IA 1 0 0 0–1
IB 2 0 0 0–1
IIA 1–2 1–2 0 0–1
IIB 3 0–2 0 0–1
IIIA 4 0–2 0 0
IIIB 4 0–2 0 1
IVA1 1–4 0–2 0 0–2
IVA2 1–4 3 0 0–2















eBSA, body surface area; NCI, National Cancer Institute (NCI-VA classi
plus B2 criteria.
resentation. It has to be noted that patients with tumors
T3) have an inferior outcome compared to those with ery-
hroderma (T4). Patients with visceral involvement (stage IVB)
re rare and have a median survival of only 2.5 years or
ess.20,23,25–27
.  Current  treatment  options  other  than
adiotherapy
everal treatment options do exist for the management of
ycosis fungoides or Sézary syndrome, and they are all sum-
arized in Table 2. The current management is based on thetage of disease, and it includes skin-directed therapies and
ocalized radiation treatment for limited disease as well as sys-
emic therapy supplemented by or integrated with total skin
lectron irradiation for more  advanced stages.n); Dutch, Dutch system. Sézary syndrome is deﬁned as meeting T4
The management of MF/SS is centered on a “stage-based”
approach and an evaluation by a multidisciplinary team is
preferred. Initial treatment in patients with patch/plaque
disease includes skin-directed therapies (localized or gener-
alized), with the addition of systemic biologic therapy for
refractory, or progressive disease. In patients with unfavorable
prognostic features (e.g., folliculotropic or large-cell trans-
formed MF, or B1 involvement) systemic biologic therapies
may be introduced earlier in the treatment algorithm. Patients
who do not respond to biologic therapy or those with very
aggressive or extracutaneous disease may be treated with
chemotherapy.28,29
4.1.  Localized  skin-directed  therapies  other  than
radiotherapy
Corticosteroids:  frequently prescribed in patient with limited
patch-stage MF (IA), producing response rates of over 90%.30,31
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Table 2 – Stage-based treatment options and results for mycosis fungoides or Sézary syndrome.
Stage Results (5 years DSS23) Treatment options
IA 100% Local  RT
Topical corticosteroids
Topical chemotherapy (i.e., nitrogen mustard or carmustine)
Topical retinoids (i.e., bexarotene or tazarotene)
Topical imiquimod
Phototherapy (UVB for patch or thin plaques; PUVA for thicker plaques)
IB–IIA IB (95%)
IIA (84%)
TSEI  in particular for patients with severe skin symptoms or generalized
thick plaque or tumor disease (TSEI followed by systemic therapies such as
interferon or bexarotene to maintain response)
IA–IIA disease with B1 blood
involvement
Not available More  intensive treatments as described for stage III with B1 blood
involvement
Patients with histological evidence of folliculotropic or large cell
transformation (LCT) are usually managed as described for treatment of
stage IIB disease
IIB 56% Limited extent tumor disease
with or without patch/plaque
disease
Local RT and an adjuvant systemic
therapy (retinoids, IFN, HDAC
inhibitors, ECP, denileukin diftitox,
methotrexate)
Systemic therapy with or without RT
and with or without skin-directed
therapy
Generalized tumor disease TSEI or systemic therapy (when use
TSEI, adjuvant therapy with systemic
therapies can be considered to
improve response duration)
Patient with LCT Systemic therapy




Biologic systemic therapies with or
without skin-directed therapy
IV 30% Sézary syndrome Single agent biologic systemic therapy
or combination therapies
Non-Sézary or solid organ
disease
Systemic chemotherapy with or
without RT for local control (adjuvant
biologic therapy may be considered
following chemotherapy to improve
response duration)Palliative treatment (see text). DSS, disease speciﬁc survival.
Class I (potent) topical corticosteroids, such as betamethasone
dipropionate 0.05% or mometasone furoate 0.1%, are the most
effective, but their long-term of use may lead to skin atrophy
or striae formation, and their use on large skin surfaces may
lead to systemic absorption. Patients with T1 disease have an
approximately 60–65% complete response (CR) rate and a 30%
partial response (PR) rate with topical steroids. Patients with
T2 disease have a 25% CR rate and a 57% PR rate.31
Topical chemotherapy (mechlorethamine and carmustine): used
for the management of MF  for many  decades.32,33 The efﬁcacy
of topical nitrogen mustard at concentrations of 0.1–0.2% in
an aqueous or ointment base is demonstrated, and a complete
response rate of up to 72% in early stage MF  with long-term
remissions (>8 years) is reported. However, long-term use is
associated with the risk of secondary epidermal cancer and a
34high rate of hypersensitivity.
Synthetic retinoids (bexarotene and tazarotene) and imiquimod:
bexarotene gel is the only FDA approved synthetic retinoid
for topical therapy in patients with MF  and SS. A phase I–IItrial involving 67 patients with early stage MF  demonstrated
a 63% ORR (CR in 21%) with a median response duration of
99 weeks.35 In a small number of series Imiquimod has been
proven to be active in patients with early stage MF  refractory to
other therapies.36–38 As skin irritation is frequently observed,
these agents may be used for localized treatment on limited
areas.
4.2.  Generalized  skin-directed  therapies  other  than
radiotherapy
These treatments are indicated in patients with widespread
skin involvement.
Phototherapy [PUVA (psoralen and UVA) and UVB]: Psoralen
plus ultraviolet (UV)-A light therapy (PUVA) with orally admin-
istered 8-methoxypsoralen (8-MOP), which sensitizes the skin
to UVA irradiation, is an important treatment for early-stage
disease.39,40 The 8-MOP may also be added to either a medi-
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fﬁcacy of broadband UVB tends to be limited to the patch
tage, whereas PUVA is also effective in clearing plaques.
In a retrospective study on patients with early-stage MF
stages IA–IIA; N = 114), treatment with narrowband UVB
N = 19) and PUVA (N = 95) also resulted in similar CR rates
68% vs. 62%) and median time to relapse (11.5 months vs.14
onths).41 The 15-year survival rates were 82% (IA) and
8% (IB/IIA).40 The most common acute adverse effects are:
rythema, pruritus, and nausea, which are usually mild at pre-
entation and generally manageable with dose adjustments of
VA, 8-MOP, or dose interruptions. Gastrointestinal adverse
ffects are associated to orally given 8-MOP.40 Patients treated
ith PUVA have an increased risk of chronic photodamage and
econdary cutaneous malignancies.42 It should be noted that
umulative doses of UV are associated with an increased risk
f UV-associated skin malignancies. Thus, phototherapy may
ot be appropriate for patients with a history of squamous or
asal cell carcinoma or melanoma.
.3.  Systemic  therapies
ystemic therapies with extracorporeal photopheresis (ECP),
nterferons, systemic retinoids, or histone deacetylase (HDAC)
nhibitors are preferred to traditional chemotherapy for
atients that are not responding to initial skin-directed thera-
ies. Multiagent chemotherapy is applied only to patients who
o not respond to multiple prior therapies (including single-
gent chemotherapy and combination regimens), or having
ulky lymph node or parenchimal disease.
Interferon: Interferon- (INF-) is one of the most widely
sed ﬁrst-line treatments in CTCL. It has a wide range
f biologic effects, including antiviral, antiproliferative, and
mmunomodulatory actions, and the overall response rate
ORR) is greater than 70% with CR rates greater than 20%.43
FN gamma  has been shown to be effective in the treatment
f patients with various stages of CTCL that is refractory to
FN alpha and other topical or systemic therapies.44 IFN- is
roposed as a ﬁrst-line therapy in stage IIB–III disease and
s a second-line treatment in early stage disease. It is gener-
lly given as a long-term therapy. Combination therapy with
FN- and PUVA has very high response rates (ORR 92%, com-
lete response 62–70%) and is superior to other combinations
ith retinoids or extracorporeal photopheresis.45,46 Almost
ll patients initially develop temporary ﬂu-like symptoms.
hronic side effects can include anorexia, fatigue, depression,
lopecia, cytopenia, and impaired liver function.45
Retinoids: Retinoids are vitamin A derivatives that have
mportant effects on cell growth, terminal differentiation, and
poptosis. They are strongly teratogenic, so conception control
efore, during and after treatment is necessary in all female
atients of child-bearing age.
ORR to retinoids (all-trans retinoic acid, 13-cis-retinoic
cid, and the synthetic analogs isotretinoin, etretinate, and
citretin) ranged from 44% to 67% and complete response
ates from 21% to 35%, with a median response duration
f about eight months. Common side effects include skin
nd mucous membrane dryness.47 Oral bexarotene, a new
ynthetic retinoid, has been evaluated for the treatment of
efractory or persistent early- and advanced-stage CTCL in two
ulticenter clinical trials48,49 that demonstrated in early stageiotherapy 1 9 ( 2 0 1 4 ) 77–91 81
disease (stages IA–IIA) refractory to prior treatment an ORR  of
54% and a disease progression rate of 21%.49 In patients with
advanced CTCL (stages IIB–IVB) refractory to prior treatments,
clinical CR and PR were observed in 45% of patients with ORR
of 55%, including 13% clinical CR.48
HDAC inhibitors: New class of drugs, potent inducers of his-
tone acetylation, cell cycle arrest and apoptosis. Vorinostat
was the ﬁrst HDAC inhibitor approved by FDA for the treatment
of patients with progressive, persistent, or recurrent CTCL, or
following two systemic therapies. The activity and safety of
the HDAC inhibitors vorinostat and romidepsin has been eval-
uated in patients with refractory CTCL.50,51 In a phase II study
involving 74 patients (median 3 prior therapies) with persis-
tent, progressive or refractory stage IB-IVA MF/SS, vorinostat
resulted in an ORR of 30% with median time to progression of 5
months.51 The response rates and median response durations
were comparable to those obtained with bexarotene capsules
and denileukin diftitox.
Romidepsin is approved by the FDA for the treatment of
CTCL in patients who failed after at least one prior systemic
therapy.
Denileukin diftitox:  is an Immunotoxin, a recombinant fusion
protein that contains the portion of IL-2 that interacts with
the IL-2 receptor (IL-2R) coupled with a truncated portion of
diphtheria toxin (DT). Denileukin diftitox was FDA approved
for the treatment of patients with persistent or recurrent CTCL
based on phase III studies.52,53
Conventional cytotoxic systemic chemotherapy:  Primary treat-
ment only for patients with advanced disease or large cell
transformation and for second-line therapy for early-stage
disease refractory to skin-directed therapies and systemic bio-
logic therapies. It consists of single-agent and combination
chemotherapy that have been associated with high response
rates, but short lived durations. Options involve single-
agent or multi-agent chemotherapy including methotrexate,
chlorambucil, vincristine, doxorubicin, cyclophosphamide,
etoposide, gemcitabine, nucleoside analogs. Combination
regimens include CHOP, CVP. Low-dose methotrexate has been
used to treat early-stage MF and SS for many  years but only
limited data are available.54,55 Low-dose MTX  has been suc-
cessfully combined with IFN-.56
Gemcitabine as a single agent has been evaluated in
patients with advanced, heavily pretreated CTCL and as front-
line therapy in untreated patients.57–59 Pentostatin has shown
activity as a single agent or in combination with IFN alpha in
patients with advanced MF  or SS.
Limited data also suggest some activity for the oral temo-
zolomide and the proteasome inhibitor bortezomib in patients
with previously treated MF.60,61
Pegylated liposomal doxorubicin has shown substantial
single-agent activity in patients with pretreated, advanced or
refractory CTCL.62
Pralatrexate: is a folate analog indicated for patients with
relapsed/refractory peripheral T-cell lymphoma (PTCL), and
has also demonstrated activity in patients with CTCL.63
Extracorporeal photopheresis (ECP): is an immunomodulatory
therapy using psoralen and UVA radiation extracorporeally. It
consists in the removal of leukocytes by leukapheresis, which
are then treated with 8-methoxypsoralen, exposed to UVA
and returned to the patient. ECP is particularly indicated in
nd ra82  reports of practical oncology a
patients with or at risk of blood involvement (erythrodermic
stage III disease or IVA with SS).64,65 A suggested mechanism
of action is the induction of apoptosis in circulating malignant
T lymphocytes and the subsequent release of tumor antigens
that lead to a systemic antitumor response against the malig-
nant T cell clone. This treatment is of particular beneﬁt in both
erythrodermic MF  and SS with circulating neoplastic T cells. A
meta-analysis of 19 studies (5 studies using ECP as monother-
apy and 14 studies as combination therapy) involving more
than 400 patients with CTCL showed a combined ORR for all
stages of CTCL of 56% (18% CR). The response rates were 58%
(15% CR) for erythrodermic disease (T4) and 43% (9.5% CR) for
SS.
5.  Localized  radiation  treatments
Radiotherapy (RT) is an important treatment option in the
management of these patients either for those with limited
stage or those with advanced stage disease. Due to the rar-
ity of this disease, there are no randomized trials evaluating
indications for RT in comparison to the other aforementioned
treatment approaches. RT can be delivered to a variable exten-
sion of the skin surface and with palliative or curative intent,
it can also be delivered together with other treatment options,
more  often not concomitantly, but in a sequential sched-
ule. Mycosis fungoides, like other hematological diseases,
is extremely radiosensitive, hence low dose treatments can
achieve a high level of response rate.66,67 The cell survival
curves indicate a D0 of 0.9 Gy and a N of less than 2. In linear
quadratic model terms, this means that there is a large compo-
nent of alpha-associated cell kill with limited repair of initial
damage and the alpha beta ratio is greater than 10.68 Impres-
sive responses to radiations had been already documented
at the beginning of the use of radiotherapy, leading to an
increasing use of this technique among dermatologists at that
time.69–72 Dose–response relationships were widely examined
in several studies showing a direct correlation between dis-
ease free interval and radiation dose.68,73 Partial regression of
disease was observed with single doses as low as 1.0 Gy but
complete response required a dose of 7.0 Gy or higher. In a
study using fractionated treatment and doses ranging from
less than 10 Gy to 40 Gy for individual plaques and tumors, Cot-
ter et al.74 demonstrated a similar response rate, i.e. 89–96%,
across the entire range of dose. However, the likelihood of local
recurrence after treatment was inversely related to dose, and
was 42% for doses less than 10 Gy, 32% for doses of 10–20 Gy,
21% for doses of 20–30 Gy, and no recurrences after doses
higher than 30 Gy.
5.1.  RT  in  unilesional  disease
Several studies reported the efﬁcacy of RT in this setting of
patients. A recent review evaluated the results of localized RT
for the treatment of 10 patients affected by MF with unilesional
or oligolesional disease (localized set of lesion, up to three
or four covering <5% of body surface area) treated from 1997
to 2010 at Cleveland University.75 In general, each patient’s
lesion was treated with an en-face ﬁeld using 6 MeV or 9 MeV
electrons prescribed to the 80–90% isodose line depending ondiotherapy 1 9 ( 2 0 1 4 ) 77–91
the thickness of the lesion. A 0.5–1-cm tissue equivalent bolus
was used daily. The treated margin was at least 2 cm.  A dose
of 30.6–36 Gy was delivered at 1.8 Gy per fraction. The radia-
tion was delivered daily, 5 days each week. In this series all
patients treated with radiation therapy achieved a complete
response veriﬁed by clinical examination within 2 months of
treatment. After diagnosis, none of the patients progressed to
a more  advanced stage of disease, within a follow-up period
ranging from 15 to 182.5 months after diagnosis (mean follow-
up of 63.9 months). The mean overall duration of response
to radiation therapy was over 40.1 months. Thirty per cent
of patients reported a relapse, with two-thirds occurring in
the previously irradiated area. Among the three patients who
relapsed the mean time to relapse was 42.3 months. Acute ery-
thema was the most common adverse event that was recorded
within 2 months after the completion of radiation therapy.
Other adverse events included acute fatigue, acute desqua-
mation, chronic ulceration, chronic erythema, and acute and
chronic dyspigmentation. In this experience, RT was well tol-
erated, with few side-effects, such as moderate erythema at
the site of radiation for a few weeks following treatment. Pre-
vious studies76–85 with a low number of patients regarding
RT for unilesional MF were also analyzed in the same review
performing a pooled data analysis showing that the 1- and
5-year disease-free survival rates after radiation therapy were
92.7% and 83.4%, respectively. Doses delivered in these studies
ranged from 20 Gy to 40 Gy and NCCN guidelines also recom-
mend a dose of 12–36 Gy.86 A good toxicity proﬁle emerged
from these studies. However, an increased risk of develop-
ment of squamous cell and basal cell carcinomas within the
radiation ﬁeld has been observed.87 Thus, the risks of radia-
tion therapy must be weighed against the potential for cure of
early-stage CTCL, a disease in which approximately 10–20% of
cases can progress to advanced disease if left untreated.88
5.2.  Local  palliative  RT
A retrospective study of palliative superﬁcial radiotherapy
showed a CR rate of 95% for plaques and small tumors (<3 cm)
and a CR rate of 93% for large tumors (>3 cm), irrespective of
dose. Use of low-dose electron beam (4 Gy in 2 Gy fractions)
allows overlapping ﬁelds to treat lesion at any site.74,89 We
have treated some cases of refractory widespread skin involve-
ment disease in Modena with low dose fraction treatments (2
fraction of 2 Gy/die up to 4 Gy) using electron beam directed
to the symptomatic lesions with a very good response rate
without side effects. These patients could also be retreated to
the same lesions or to other lesions if necessary without any
problem (Fig. 1a).
6.  Total  skin  electron  beam  irradiation
(TSEI)
Modern TSEI has an overall response rate approaching 100%
and it remains a very important treatment for mycosis fun-
goides, with no other treatment having shown such a high
response rate. However, it is a very complicated treatment
requiring a skilled multidisciplinary team, highly experienced
in the management of cutaneous lymphoma.90 Although
reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 77–91 83
Fig. 1 – (a) Regional palliative treatment of a lesion of MF  (2 Gy/fraction up to 4 Gy; 8 MeV electron beam with 0.5 cm bolus):














sreliminary experiences of total-skin irradiation using X-rays
ere attempted by several dermatologists during the ﬁrst
ecades of the twentieth century,91,92 TSEI could be developed
nly after the implementation of linear accelerators (second
art of the twentieth century) due to the availability of elec-
ron beam therapy. In fact, the use of X-rays was burdened
f systemic effects, like acute dermatitis, agranulocytosis and
eath, while the depth dose characteristics of the electron
eam made it possible to treat large surfaces of the skin in single ﬁeld, concentrating the dose of irradiation in the
uperﬁcial tissue including epidermis and upper dermis, while
imiting the radiation dose that reaches the deep dermis and
ubcutaneous tissue.686.1.  Treatment  techniques
A conventional linear accelerator for total skin treatment with
electrons was ﬁrst utilized at Stanford,93 but the use of elec-
tron beams to treat the entire skin was already described in
1952. Trump and coworkers used a well-collimated electron
beam (“cathode ray ribbon beam”) generated by a Van de Graff
accelerator aimed downward at a recumbent patient on a
motorized table to irradiate the entire skin.94 IAEA’s classiﬁca-
95tion of TSEI techniques includes three different modalities.
With translational techniques,  the patient is translated on
a stretcher through an electron beam of sufﬁcient width to
cover the patient’s transverse dimensions; with large electron
nd ra84  reports of practical oncology a
ﬁeld techniques,  a standing stationary patient is treated at a
large SSD with a single large electron beam or a combination
of large electron beams; ﬁnally, with rotational techniques the
patient is standing on a rotating platform in a large electron
ﬁeld. Dosimetric, geometric and patient positioning details are
reported in AAPM Report No. 23.96
A recent review of Diamantopoulos et al. compared differ-
ent techniques describing their advantages and disadvantages
as well as the dosimetric problems.97 Single scattered horizontal
beam needs large treatment rooms in order to obtain a correct
distance of the patient from the accelerator (SSD 7 meters)
determining homogenous electron ﬁeld and is burdened of
X-ray contribution to total absorbed dose.96 Multiple dual ﬁeld
technique combines 4–8 pairs of angled electron beams. Each
pair creates a composite large ﬁeld that corresponds to a differ-
ent orientation of the body. At Stanford, a four-ﬁeld technique
was utilized at ﬁrst, and later, a six-ﬁeld technique of treat-
ment was introduced.93,98 In general, the dosimetry of total
skin electron irradiation improves as the number of treatment
ﬁelds increases.99 With a four-ﬁeld technique, there is signiﬁ-
cant overlap of adjacent ﬁelds, creating “hot spots” which may
result in long-term effects such as telangiectasia, subcuta-
neous ﬁbrosis and even necrosis.68 In a typical set up, patients
are treated in the standing position at a distance of 3.5 m from
the isocenter. A Lucite plate is placed as close as possible to
the patient surface in order to degrade and further scatter the
electrons. During treatment, the machine is angled upwards
or downwards at an angle of 18◦. The combination of these
two ﬁelds for treating each body surface results in an ade-
quate homogeneous dose distribution at the patient’s surface
and minimizes photon contamination, which is greatest in
the central axis of the beam. The most widely used variant of
this technique is the six-pair dual ﬁeld technique also known
as “Stanford technique”100 (Fig. 2). The patient is placed in
all six positions (anterior, posterior and four opposed oblique
ﬁelds), with a dual-ﬁeld irradiation at each position, the six
patient orientations being spaced at 60◦ intervals. Treatment
is administered over a 2-day period. On day 1, the anterior
and two posterior oblique ﬁelds are treated at each of the
two accelerator angles. On day 2, the posterior and two ante-
rior oblique ﬁelds are treated at each of the two accelerator
angles. The major advantage of this modality is its ease of
application even in small treatment rooms. Furthermore, as
the two central axes of each beam point outwards patient’s
body, X-ray contribution to total absorbed dose becomes less
signiﬁcant as its main concentration is close to the central axis
of the beam. The proper angle of the component beams ranges
from ±10◦ to ±25◦ and depends on each beam characteris-
tics and the source-to-skin distance used in every center.97
Rotational TSEI reduces dramatically total treatment time, a
horizontal beam101 can be used but a combination of two
large electron ﬁelds can also be used.102,103 The ﬁrst trans-
lational technique was developed at the Christie Hospital in
England104; a modiﬁcation of this initial technique was applied
at the Northern Israel Oncology Center105 and it demands a
stationary reclined patient at the same SSD while the large
electron ﬁeld is created by 4–5 pairs of transversally angled
beams. This technique and its modiﬁcations overcome the
difﬁculties related to available treatment space and patient
comfort, but they add to the dosimetric uncertainty aboutdiotherapy 1 9 ( 2 0 1 4 ) 77–91
ﬁeld junctions.106 A comparison between the Modiﬁed Christie
Hospital Translational Technique and the Stanford Technique
revealed no statistical difference in response rate, disease-
free survival and overall survival between the two  irradiation
techniques, but it also showed that the Stanford technique
was signiﬁcantly less toxic.107 Combined techniques,  combining
Stanford-like ﬁelds with different patient set-ups in total skin
treatment are very common and some clinics developed their
own variants. A very usual modiﬁcation is the use of Stanford
ﬁelds on a rotating patient. This mode enables treatment to
be carried out at a short period of time and at relatively short
source skin distances.97 “Six dual ﬁeld technique” or “Stan-
ford technique” and its variants108 is used in more  than 80%
of radiotherapy centers carrying out TSEI during two  or three-
day treatment. Rotational techniques either with one ﬁeld at a
large SSD or Stanford-like dual ﬁeld directed toward a rotating
patient, are employed in 12% of cases.97 Techniques that use
a reclined patient position are the minority in TSEI treatment.
Although they are not widespread, these techniques have the
advantage of turning TSEI irradiation into a rather comfortable
procedure for the patient. The widespread use of the six dual
ﬁeld technique can be related to its dosimetric results that
can be achieved with single ﬁeld techniques109 even in small
rooms (SSD = 2.85 m110 to 4.25 m111). The modiﬁed Stanford
technique using modern linear accelerators represents, there-
fore, a standard technique in current clinical trial protocols.
The Stanford protocol involves treating three positions each
day so that a full cycle of treatment to the six standing posi-
tions is delivered over 2 days. The full-dose Stanford schedule
prescribed is 2 Gy per cycle to a total dose of 30–36 Gy over 9–10
weeks. A week gap in treatment can be added to provide relief
from the skin radiation reaction, and to provide patients who
travel a rest. Treatment typically takes 30–40 min  each day.90
6.2.  Dose  prescription
The Stanford data112 showed an increased rate of complete
response for increasing dose with complete response rate
of 18% for doses less than 10 Gy, 55% for 10–20 Gy,  66%
for 20–25 Gy, 75% for 25–30 Gy, and 94% for doses of 30 Gy
or greater. Maintenance of complete response with time
was greater among patients treated with high dose (25 Gy
or higher). The impact was most dramatic among patients
with generalized plaque disease, where 50% maintained a
complete response after high-dose therapy, but only about
10% remained disease-free after low-dose therapy. Split-dose
experiments showed no difference in tumor regrowth at treat-
ment intervals of one or seven days, suggesting little recovery
between treatment fractions; this allows the use of protracted
fractionation schemes, limiting the effects on normal tissues
and also increasing the “therapeutic ratio”.68
According to the EORTC recommendations,113 objectives
of any total skin electron radiation technique should be: (1)
to align the dose distribution to the target volume; (2) to
be practical, comfortable, and efﬁcient for the patient; (3) to
provide sufﬁcient dose within the target volume; (4) to reliably
attain cutaneous remission; (5) to minimize toxicity; (6) to pro-
duce beneﬁcial long-term clinical results; (7) to accommodate
repeated administration as required.
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Fig. 2 – “Stanford technique”: six set-up positions of patient (anterior, posterior and four opposed oblique ﬁelds), with a



































The primary target volume includes the epidermis, adnexal
tructures, and the dermis114,115 which may receive the major-
ty of the deposited ionizing energy. The 80% isodose should
e at a depth of at least 4 mm under the skin surface, and
he dose at a depth of 20 mm should be less than 20% of
he maximum dose at the skin surface. The photon contam-
nation at the level of the bone marrow must be less than
.7 Gy for a full course of TSEI to avoid hematological seque-
ae.
The primary goal is to administer at least 26 Gy at a depth
f 4 mm in truncal skin along the primary axes.116 For an effec-
ive electron energy of about 4 to 5.5 MeV,  the truncal surface
ust receive about 31–36 Gy. The human body has a com-
lex surface that presents the greatest technologic challenge
or any technique of TSEI. A homogeneous dose-distribution
hould be gained increasing the number of ﬁelds, it is also nec-
ssary to position the patient to maximize unfolding of skin
n order to reduce as much as possible the underdosed areas
nd to top-up regions of lesser dose (i.e. setting the joints of
he limbs at appropriately large angles, slightly bending the
orso and hips to expose folds in the lower trunk). Use of the
tanford University technique requires patients to stand dur-
ng treatment, in contrast to a prone-supine method. When
tanding, some patients may beneﬁt from support provided by
 posterior frame against which they may lean or by thin encir-
ling straps that help hold them up and orient them to their
ositions. At least 6 beams must be administered, unless a
ethod of dynamic rotation is used.117,118 The globe of the eye
ust not receive more  than 15% of the prescribed skin surface
ose. A combination of internal and external eye shields will
nsure that 26 Gy is administered to the eyelids while protec-
ing the globes. Optional shields (e.g., to the scalp or testes) are
ot recommended. It may be necessary to place small shields
ver pacemakers and ostomy sites, but this may compromise
fﬁcacy.6.3.  Regional  patch  and  boost  treatments
Usually, some parts of the body surface are “shadowed” and
receive relatively lower total doses of irradiation.119,120 These
areas include the top of the scalp, the perineum and the
soles of the feet. Other areas may be problematic in individ-
ual patients because of body habitus, such as underneath the
breasts of some women and under the panniculus of obese
individuals. Separate treatments can be administered to these
areas using a direct electron ﬁeld. Without a scalp reﬂector,
the vertex can be patch-treated. A comparison of published
10-year data from Hamilton, Yale, and Stanford Universities
and several other series suggest that progression-free survival
might be improved by 10–20% by applying patch treatments.113
The dose prescribed at peak (at the skin surface of the soles)
is 26–28 Gy. Results vary among patients, and measurements
may inﬂuence the prescription of patch treatments. Mea-
surements with thermoluminescent or ﬁlm dosimeters are
typically conducted during the ﬁrst 2 weeks of TSEI and over
one cycle of all ﬁelds or beams.
Some patients with a discrete number of tumor lesions
will receive boost treatment to these tumors at the outset
of electron beam therapy in order to reduce their thickness
and permit better penetration by the TSEI electrons. Usually,
doses of 15 Gy in 1.5–3.0-Gy fractions using 6–9-MeV electrons
are adequate for this purpose.68 Boost treatments may reduce
symptoms on the hands, feet, or face and may begin the heal-
ing of any skin ulcers. When the dose is administered 1–2
weeks before TSEI, a prompt response facilitates a course of
TSEI reducing immediate adverse effects. Custom lead made
goggles are proposed to shield the eyes, and the eyelids can be
patch treated with radiotherapy following TSEI. Perspex hand
blocks or lead-lined gloves can be used for the hands, shielding
can be added to the TSEI frame to shield the lower legs and the
head and neck area if needed. Lead ﬁnger nail shields can be
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used if there is no involvement of these areas. The testicles
can be shielded by using a lead-lined cricket box.
6.4.  TSEI  toxicity
TSEI is generally not burdened by heavy acute and late
toxicity.121 Usually, patients who  are ﬁt can continue normal
activities of daily life. With the dose of 30–36 Gy, patients may
experience some temporary short-term side-effects: namely,
fatigue is common but generally not severe or debilitating, MF
skin lesions become more  erythematous and the skin develops
a mild to moderate radiation dermatitis. Complete, temporary
scalp alopecia (usually after 2 weeks of treatment) and tempo-
rary nail stasis appear in 100% of the patients. Hair typically
returns, but the color and texture of the hair when it regrows
may be different. Nails may become brittle, and half of the
patients can develop some edema of hands and feet. Less than
10% of patients can develop minor nosebleeds. Other uncom-
mon  side effects are: blisters on the ﬁngers and feet (<5%, soft
comfortable footwear is advised to prevent it), self-limiting
anhidrosis, minor parotiditis, and gynecomastia in males (<3%
each), corneal tears from internal eye shields (<1%), chronic
nail dystrophy, chronic xerosis, partial but permanent alopecia
of the scalp, and ﬁngertip dysesthesias that persist for more
than a year (<1% each).113 Infertility is possible in men  but it
is not common in women.
Acute or late mortality related to the procedure has never
been described. Patients often ﬁnd the lead goggles used to
shield the eyes uncomfortable. It is important to monitor for
infection during treatment. In patients with early disease,
the reported incidence of infection is 1%,121 but in patients
with more  advanced disease the incidence of skin infection is
higher. The lesions of mycosis fungoides continue to respond
for up to 3 months, and the assessment of response to TSEI
should not be carried out too early. Yale published on patients’
perspective of TSEI and found out that TSEI is perceived to
be a successful treatment but also difﬁcult to perform and to
recover from in comparison with other treatments.122
6.5.  TSEI  clinical  indications
According to EORTC guidelines,113 TSEI can be used for
patients at all stages of mycosis fungoides, and remains a very
important treatment for these patients, even for those with
SS. The response rates and duration of response are higher in
earlier stage disease. The aim of treatment (curative or pallia-
tive) varies depending on the stage. In a retrospective series
of 141 patients with initial-stage disease IA (T1 N0 M0) and
IB (T2 N0 M0)  of the University Hospital of Dijon123 treated
with a 6-MeV linear accelerator to a mean total dose of 30 Gy,
2 Gy/day, 4 days/week, for 4 weeks, the overall response rate
was 94.7%. A complete response was achieved in 87.5% of T1
and 84.8% of T2 patients. After a median follow-up of 114
months for the whole group, 5-year DFS rate was 50% and
OS rate was 65%. Electron-beam irradiation is more  penetrat-
ing than other skin-directed treatments (e.g., topical nitrogen
mustard [HN2] or phototherapy) and is generally considered a
rational ﬁrst line therapy for patients with T2-classiﬁed (i.e.
generalized patch or plaque) and T3-classiﬁed (i.e. tumors)
disease.68,124 The efﬁcacy of TSEI in erythrodermic MF (i.e. T4diotherapy 1 9 ( 2 0 1 4 ) 77–91
disease) is more  controversial.125 The Stanford University126
recently reported its experience with TSEI in the treatment
of patients with mycosis fungoides at stage IB (generalized
patch or plaque T2N0M0) and stage IIB (tumor T3N0M0). They
analyzed retrospectively data of 180 patients treated at their
institution from 1970 through 2007 with TSEI as monother-
apy comparing this group with subgroups receiving adjuvant
nitrogen mustard (HN2). The TSEI was administered using the
six dual ﬁeld technique, with a dose of 1.5–2 Gy per 2-day
cycle.100 Most patients received a total dose of 36 Gy (range,
30–40 Gy), and local boost treatments (10–15 Gy) were often
delivered to tumor lesions or thick plaques, “shadowed” areas
of the body were routinely supplemented with electrons or
orthovoltage irradiation (median dosage, 20 Gy) for compen-
sation. The overall response rate was 100%; 60% of patients
achieved a complete clinical response (T2 cases, 75%; T3 cases,
47%). The 5- and 10-year OS rates of the entire cohort were 59%
and 40%, respectively. There were no signiﬁcant differences
in freedom from relapse, overall survival, and progression-
free survival disease between TSEI monotherapy and TSEI
with adjuvant HN2. Authors stated that a TSEI of 30 Gy or
greater is highly effective in treating T2-T3 MF, with bet-
ter outcomes in T2 disease. Patients with stage III disease
have diffuse erythroderma involving the entire skin surface.
The rate of remission with TSEI is about 75%, although all
patients experience relief of major symptoms. The overall 5-
year progression-free survival is 26%. However, there are two
subgroups of patients: those with and those without blood
involvement. Patients without blood involvement (i.e. those
who are B0) may be treated with TSEI to prolong progression-
free survival because two thirds of them remain disease-free
at 10 years after TSEI.125 TSEI may instead be offered for pal-
liation only to B1-patients. The 10-year disease-free survival
for this subgroup is 15%. TSEI may be repeated if necessary.
The addition of extracorporeal photoimmune chemotherapy
or PUVA to TSEI remains experimental.
6.6.  TSEI  palliative  setting
TSEI may be proposed for patients with stage IVA (N2-3) and
stage IVB (M1) disease with palliative intent. The chance of
complete remission in the skin is around 70%. Some patients
with stage IVA disease may have complete cutaneous remis-
sions for 5–10 years, but the 10-year progression-free survival
is low. In contrast, all patients with stage IVB disease die of MF
within 5 years from TSEI, but this treatment is very effective
for palliation and improves quality of life. TSEI can be used
as a second line treatment after the failure of other therapies
and patients typically experience disease clearing.113 Intro-
caso et al.127 employed TSEI in four patients with SS obtaining
signiﬁcant improvement in their blood burden of malignant
cells in addition to complete cutaneous responses to total skin
electron beam therapy. They point out the potential for TSEI as
both a skin and blood tumor debulking agent, and not merely
to a palliation for skin symptoms.Hauswald et al.128 recently reported treatment results of
25 patients with cutaneous manifestations of advanced and
therapy-refractory cutaneous lymphoma (17/25 patients T-
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993 and 2010. All patients were symptomatic. The median
otal dose was 29 Gy, applied in 29 fractions of median 1 Gy
ach. The median follow-up time was 10 months. Treatment
esponse regarding palliation with symptom relief, especially
f pruritus and regression of cutaneous lesions, was achieved
n 23 patients (92%). A clinical complete response was doc-
mented in 13 (52%) and a partial response in 10 patients
40%).
.7.  TSEI  repeating  and  low  dose  TSEI
nvestigators at Yale University129,130 and, subsequently, at
tanford University,128 reported the successful administration
f multiple courses of TSEI. Occasionally, it is also possi-
le to administer a second complete course of “high” dose
SEI. However, most patients receive lower dose TSEI during
he second or third course. The goal is to relieve symptoms
hile avoiding long-term adverse effects. With minimal appli-
ations of TSEI, consisting of several fractions to a dose of
–8.0 Gy, administered every 3–18 months, the treatment may
e safely given to control disease with minimal toxicity.
The Stanford update reports on 14 patients retreated with
 second course of TSEI to a dose of 24 Gy. All 14 patients
esponded and two  patients had a complete response.126
Interest in the CTCL community is now focusing on low-
ose TSEI after a recent Stanford review131 on 102 patients
reated with less than 30 Gy. The overall response rate was
0–98%. The relapse-free period after TSEI was 22.2 months
ith more  than 30 Gy, 29.3 months in the 20–30 Gy group, 25.7
onths in the 10–20 Gy group and 12 months in the 5–10 Gy
roup.
.8.  Association  of  TSEI  with  other  treatment
odalities
 trial randomizing patients to observation or vorinostat after
ow-dose TSEI has recently opened to accrual in the USA.132
he use of adjuvant PUVA and topical mechlorethamine after
SEI has been reported, but the data are limited and retrospec-
ive. The data on PUVA are based on only 14 patients133 and it is
uggested that PUVA can maintain remission after TSEI. Initial
esults from Stanford in 1999 reported higher response rates
nd longer freedom from relapse using mechlorethamine as
n adjuvant after TSEI,134 but their more  recent data update
ith TSEI in the modern era do not conﬁrm this ﬁnding.126
n patients with blood, lymph node or visceral involvement,
SEI can be used to control disease in the skin sequentially
ith other treatments such as chemotherapy. The response
ates in the skin are high, but the duration of response is short
t 2–3 months. In selected patients who are ﬁt for a reduced
ntensity allogeneic hematopoietic stem cell transplantation
HSCT), TSEI can be considered as debulking treatment. Duvic
t al.135 reported the successful use of TSEI in 18 patients with
dvanced stage IIB–IVB mycosis fungoides before allogeneic
SCT. Among these patients, 14 had stage IV disease with
nvolved lymph nodes or bone marrow, and 11 were erythro-
ermic with B2 blood involvement. All patients had received
rior treatments (median 4): with a median follow-up of 19
onths (range 1.3–8.3 years) 11 patients remain in complete
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6.9.  New  radiotherapy  technologies  opportunities
New RT technologies such as Tomotherapy may open new
treatment approaches to treat patients with MF. Several
papers in the literature report on the use of image-guided-
radiation-therapy (IGRT) to treat large skin volumes saving
organs at risk with palliative intent.90,136 In Modena we
have recently treated with tomotherapy a 38-year-old female
patient affected with a refractory MF  who was already treated
with multiple chemotherapy and biological approaches and
who was affected with mental retardation. She was referred
to our center because of a symptomatic (itch and pain) large
involvement of the skin face, which was covered by multi-
ple large tumor lesions (Fig. 1b). Our choice was driven by
the need to give a homogeneous dose to a target volume
located under the skin surface at a depth larger than that we
could adequately cover with an electron beam, particularly
in a highly irregular anatomic region like the face and the
neck. The patient was treated with a hypofractionated regi-
men (3 Gy/die, 15 Gy total dose), with a very good response.
During the treatment she experienced acute erythema and
edema of the skin and after two weeks a complete response of
all irradiated lesions was observed, with complete regression
of the acute symptoms.
7.  Conclusions
Treatment of MF and SS is still a challenge, and these dis-
eases should be managed by a skilled multidisciplinary team.
An overview of all the treatment strategies available for each
stage of the disease has been reported in Table 2: radiothe-
rapy remains a valid treatment option for all the stages of the
disease.
The extreme radiosensitivity of these disorders offers a
good therapeutic ratio for curative or palliative setting for most
patients, and the newest RT technologies may offer new possi-
bilities, taking into account technical and dosimetric problems
related to electron beam irradiation.
Some priorities for clinical research are suggested by the
rarity of the disease, the variety of potentially effective treat-
ment modalities that are currently available (from different
physical agents, to many  drugs, or a combination of the two),
and the challenging radiotherapy technical problems to be
solved. Multicenter clinical trials aimed at deﬁning the best
ﬁrst-line treatment stage by stage, the minimum effective
radiotherapy dose both for palliation and for cure, and the pos-
sible need of elective multimodality therapy, as well as the role
of the novel irradiation technologies are strongly warranted
and should be pursued by experienced reference centers.
Moreover, in order to develop and share adequate National
and International guidelines, perspective multicenter accu-
mulation of clinical data in nationwide repositories, including
detailed data relative to radiotherapy-treated patients, should
also be encouraged.Conﬂict  of  interest
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